Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 10,533 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital Diseases Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Genetics and Psychopathology in the 22q11 Deletion Syndrome

NCT00161109
View directory record Official record
Conditions
Chromosome 22q11.2 Deletion Syndrome
Interventions
Not listed
Lead sponsor
UMC Utrecht
Other
Eligibility
8 Years to 20 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2006 · Synced Oct 16, 2026, 2:15 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Feasibility and Acceptability of Amani

NCT07648043
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Amani
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Completed No phase listed Observational

Molecular Analysis of Microphthalmia/Anophthalmia

NCT00011843
View directory record Official record
Conditions
Anophthalmos
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers

NCT00503035
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Celecoxib, Colonoscopy Biopsy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 16, 2026, 2:15 PM EDT
Terminated Not applicable Interventional Results available

Vitamin D Deficiency and Atopic Dermatitis

NCT01337635
View directory record Official record
Conditions
Atopic Dermatitis, Vitamin D Deficiency
Interventions
Vitamin D
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

NCT02656017
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
Kyongtae Ty Bae, M.D., Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

NCT02117713
View directory record Official record
Conditions
Alagille Syndrome
Interventions
LUM001 (Maralixibat)
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 18 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 16, 2026, 2:15 PM EDT
Not listed Phase 3 Interventional

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

NCT03023540
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease, Type IA
Interventions
PXT3003
Drug
Lead sponsor
Pharnext S.C.A.
Other
Eligibility
17 Years to 67 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Gainesville, Florida • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

NCT06258213
View directory record Official record
Conditions
Gout, Acute Gout Flare, Gout Flares
Interventions
ABP-745, Placebo
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial

NCT04344860
View directory record Official record
Conditions
Von Willebrand Diseases, Postpartum Hemorrhage
Interventions
Recombinant Von Willebrand factor, Tranexamic Acid Injection [Cyklokapron]
Drug
Lead sponsor
Nicoletta C Machin
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Standing Cognition and Co-morbidities of POTS Evaluation

NCT03602482
View directory record Official record
Conditions
Postural Tachycardia Syndrome, Ehlers-Danlos Syndrome
Interventions
Standing, Supine
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
13 Years to 60 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

NCT02452476
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
CHF5633, Poractant alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Arginine as a Treatment for Sickle Cell Anemia

NCT00513617
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Arginine, Placebo
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
5 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
17
States / cities
Oakland, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Assess Cancer in Ovarian Tumors With Biomarkers.

NCT00436189
View directory record Official record
Conditions
Ovarian Tumor
Interventions
Blood Draw
Procedure
Lead sponsor
Ciphergen Biosystems
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Hoover, Alabama • Phoenix, Arizona • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2008 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Not applicable Interventional Results available

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

NCT06350474
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
Other
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 16, 2026, 2:15 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease

NCT03599076
View directory record Official record
Conditions
Huntington Disease
Interventions
HD Wear
Other
Lead sponsor
BioSensics
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 16, 2026, 2:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bilistick Point-of-care System 2.0 Bilirubin Validation

NCT06058910
View directory record Official record
Conditions
Neonatal Screening, Kernicterus, Newborn Jaundice, Point-of-Care Testing
Interventions
Bilistick System 2.0 point-of-care testing device
Diagnostic Test
Lead sponsor
Kettering Health Network
Other
Eligibility
Up to 2 Weeks
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 16, 2026, 2:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glycemic Monitoring in Cystic Fibrosis

NCT02211235
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 25 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF

NCT01303068
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
13C urea breath test Kit
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Exercise Training Study for Patients With Cystic Fibrosis

NCT00609050
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Self-Regulated Exercise with Telephone Reinforcement, Standard Treatment, Qualitative Approach
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
10 Years to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 16, 2026, 2:15 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes

NCT07408518
View directory record Official record
Conditions
Digestive Disease, Gut Health
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Synbiotic Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

NCT04155190
View directory record Official record
Conditions
Recurrent Basal Cell Carcinoma
Interventions
Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Apple Valley, California • Colton, California • Fremont, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Active, not recruiting Not applicable Interventional Results available

Delayed Cord Clamping With Oxygen In Extremely Low Gestation Infants

NCT04413097
View directory record Official record
Conditions
IVH- Intraventricular Hemorrhage, Extreme Prematurity, Hypoxia Neonatal, Hyperoxia, Respiratory Insufficiency
Interventions
Delayed Cord Clamping with Low Oxygen concentration, Delayed Cord Clamping with High Oxygen concentration
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
22 Weeks to 28 Weeks
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Davis, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Ensuring Patients' Informed Access to Noninvasive Prenatal Testing

NCT03420274
View directory record Official record
Conditions
Genetic Disease, Genetic Syndrome, Prenatal Disorder, Prenatal Maternal Abnormality, Pregnancy Complications
Interventions
NEST, Usual care
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 16, 2026, 2:15 PM EDT